Drug intelligence / Profile preview

methenamine + methylthioninium

Development stage: Phase 4
Lead developer: Fundação Educacional Serra dos Órgãos
Modality: Small Molecules
Administration: Oral

Overview

A combination drug consisting of methenamine and methylthioninium (methylene blue) used as a urinary antiseptic for the treatment and prevention of urinary tract infections. This combination works through complementary mechanisms: Methenamine functions by breaking down in acidic urine to release formaldehyde, which has antimicrobial properties against bacteria in the urinary tract[1][2]. Methylthioninium (methylene blue) acts as an oxidation-reduction agent that contributes to the antiseptic properties of the combination[6]. Together, these compounds help reduce UTI symptoms, particularly dysuria (painful urination)[3][5].

Brand names: Sepurin
Other names: methenamine + methylene blue

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on methenamine + methylthioninium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methenamine + methylthioninium.

Explore the full profile